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)e development of nanostructures for therapeutic purpose is rapidly growing, following the results obtained in vivo in animal
models and in the clinical trials. Unfortunately, the potential therapeutic efficacy is not completely exploited, yet. )is is mainly
due to the fast clearance of the nanostructures in the body. Nanoparticles and the liver have a unique interaction because the liver
represents one of the major barriers for drug delivery. )is interaction becomes even more relevant and complex when the drug
delivery strategies employing nanostructures are proposed for the therapy of liver diseases, such as hepatocellular carcinoma
(HCC). In this case, the selective delivery of therapeutic nanoparticles to the tumor microenvironment collides with the tendency
of nanostructures to be quickly eliminated by the organ.)e design of a new therapeutic approach based on nanoparticles to treat
HCC has to particularly take into consideration passive and active mechanisms to avoid or delay liver elimination and to
specifically address cancer cells or the cancer microenvironment.)is review will analyze the different aspects concerning the dual
role of the liver, both as an organ carrying out a clearance activity for the nanostructures and as target for therapeutic strategies for
HCC treatment.
1. Introduction
Nanotechnology is nowadays widely used for the disease
diagnosis, delivery, and targeting of therapeutics for several
types of cancers. A key role in the success of the therapeutic
use of nanoparticles (NPs) is strongly played by the clearance
rate occurring in the body. Published data reported that up to
99% of the NPs injected in the bloodstream are cleared,
mainly by the liver. )is process can affect the efficacy of NPs
to effectively reach their target and exert a therapeutic effect
[1], as well as potentially increase the risk of unwanted liver
toxicity [2]. Biodistribution studies have demonstrated that
the clearance action exerted by the liver is confirmed for the
majority of NP designs: polymeric NPs [3–5], micelles [6, 7],
quantum dots [8], gold NPs [9], and carbon nanotubes [10].
In this context, injected nanomaterials usually accumulate in
the liver and in an amount that depends on their physi-
ochemical properties, such as size, shape, and surface func-
tionalization, although relatively little is understood about
dynamics of NP transport at the intraorgan level [11, 12]. In
the liver, clearance is also facilitated by the fact that, whenNPs
enter and traverse this organ, their velocity is reduced ap-
proximately 1000-fold, increasing the interaction between
NPs and liver cells, subsequently favoring clearance [1].
NPs and the liver have a unique interaction in the body
because the liver represents one of the major barriers for
drug delivery. )e interaction between NPs and the liver
becomes even more relevant and complex when the drug
delivery strategies employing nanostructures are proposed
for the therapy of liver diseases, such as hepatocellular
carcinoma (HCC). In this case, the selective delivery of
therapeutic NPs to the tumor microenvironment especially
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collides with the tendency of nanostructures to be quickly
eliminated by the liver.
HCC represents the sixth most common form of cancer
worldwide. HCC usually arises from a preexistent liver
disease, frequently a cirrhotic state, and is associated with
well-defined risk factors including chronic viral type B and
type C hepatitis, alcohol intake, and exposure to aflatoxin
[13, 14]. Several therapeutic options can be applied at the
early or intermediate stage of the disease including liver
transplantation, resection or radiofrequency ablation (early
stage), transarterial chemoembolization (TACE), or radio-
embolization (intermediate stage). Nevertheless, the early
stages of the HCC disease are frequently asymptomatic
leading to disease detection in advanced stages. In this
clinical setting, the treatment with the multikinase inhibitor
sorafenib is the most common treatment option [13–15].
Very recently, immunotherapy by using immune checkpoint
inhibitors has been considered as a useful treatment option
for HCC [16].
)e design of a new therapeutic approach based on NPs
to treat HCC has to particularly take into consideration
passive and active mechanisms to avoid or delay liver
elimination and to specifically address cancer cells or the
cancer microenvironment.
)is review will analyze the different aspects concerning
the dual role of the liver, both as an organ carrying out a
clearance activity for the nanostructures and as target for
therapeutic strategies for HCC treatment.
2. Mechanisms Involved in the Hepatic
Clearance of NPs
)e liver is the largest gland in humans. It is connected to
two important blood vessels, the hepatic artery and the
portal vein. )e hepatic artery transports blood enriched of
oxygen from the aorta whereas blood carried by the portal
vein is enriched in digest nutrients from the gastrointestinal
tract, spleen, and pancreas. Both blood vessels subdivide into
liver sinusoids, small capillaries that lead to hepatic lobules.
Hepatic lobules consist of plates of hepatocytes and pa-
renchymal cells, radiating from a central vein. Each hepatic
lobule is characterized by a portal triad that is constituted by
five structures, a branch of hepatic artery, a branch of portal
vein, a branch of the vagus nerve, a bile duct, and lymphatic
vessels. Liver sinusoids are lined with two types of cells,
sinusoidal endothelial cells and Kupffer cells. Hepatic stellate
cells are nonparenchymal cells located in the perisinusoidal
space, the space between a sinusoid and a hepatocyte
(Figure 1). In the sinusoidal lumen are also often present
intrahepatic lymphocytes [17]. While not apparent histo-
logically, the sinusoid is functionally heterogeneous. Studies
have shown that hepatocytes are characterized by a different
gene expression throughout the sinusoid that is driven by
different gradients in oxygen tension, substrate, and hor-
mone concentrations [18–20]. )e Kupffer cells are liver
tissue resident macrophages characterized by highly dif-
ferentiated surface receptors for the uptake of pathogens and
foreign bodies passing through blood. Kupffer cells (that
represent 80–90% of total body macrophages) are
responsible for the most part of phagocytic activity in the
liver. Kupffer cells, together with blood-circulating mono-
cytes and splenic (red pulp and marginal zone) macro-
phages, constitute the mononuclear phagocyte system
(MPS), which is responsible for the sequestration of more
than 95% of NPs which consequently fail to reach their
specific target [21, 22]. )e uptake rate of NPs depends
strongly on size, surface charge and ligand chemistry, and
shape. It was observed that NPs, sizing several hundreds of
nanometers (from 400 nm to 600 nm), are preferentially
phagocyted by these cells. Also, NPs with a cationic surface
are preferentially eliminated by the Kupffer cells when
compared to NPs with neutral charged surface (i.e., poly(-
ethylene glycol)—PEG). Similarly, NPs with anionic surface
could be easily eliminated since their negative surface charge
can absorb circulating positively charged serum proteins
forming a “protein corona,” subsequently favoring their
interaction with the receptor macrophages. Also, NP shape
can influence the behavior of NPs in the bloodstream and
their distribution. )ere are no consistent data suggesting
the best NP shape for a low clearance. Interestingly, studies
reported that the rod-shaped NPs showed a reduced
clearance when compared to the clearance rate of spherical
shaped NPs; this is probably due to the presence of a few
accessible binding sites available for macrophage interaction
[23–25]. )e resident macrophages have been observed in a
3 : 2 ratio in the periportal versus the pericentral region.
)e hepatocytes in the liver endocytose NPs and can
release them either back into the bloodstream or into the
bile. However, this process occurs at a much lower rate
compared to the Kupffer cells. Interestingly, the hepatocyte
uptake was only seen when large doses of NPs are given or
when macrophages are chemically depleted [26]. Once
processed by hepatocytes, these NPs are cleared through bile
into the feces. In particular, NPs that interact with hepa-
tocytes can be processed and cleared from the body via the
hepatobiliary system. )is process starts when injected
nanomaterials, circulating in the bloodstream, slow down
when they enter the liver via the portal vein. )is allows the
nanomaterials to interact with a variety of cells, but to
successfully transit through the biliary system, NPs must
avoid being taken up by liver-resident Kupffer cells [27].
Depending on their physicochemical properties, first of all
on their size, NPs smaller than the diameter of sinusoid
fenestrations (50–150 nm) can freely diffuse into the Disse
space and can be taken up by hepatocytes [17, 28]. )ere are
also other factors that can more likely favor the uptake of
NPs by hepatocytes, in particular, PEGylation and NP
positive surface charge [29, 30]. Hepatobiliary clearance is
generally an active process promoted by transporters and
realized by many drug-metabolizing enzymes and then
followed by secretion into the bile duct via bile canaliculi or
either back into the bloodstream [26, 31]. However, the
hepatocyte uptake occurs only with smaller size NPs (less
than 50 nm) or when large doses of NPs have been injected
or if macrophages have been chemically depleted [26, 32].
A minor role in NP clearance is also performed by the
liver sinusoidal endothelial cells (LESCs). LESCs constitute
about half of the nonparenchymal cells of the liver.
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Structurally, these cells separate the hepatocytes from the
blood of the sinusoidal lumen, lack a basement membrane,
and have fenestrate sizing from 100 nm to 150 nm, therefore
allowing the passage of small NPs [33, 34].
)e internalization of NPs in eukaryotic cells can be done
through macropinocytosis, clathrin-mediated or caveolin-
mediated endocytosis, or additional endocytic pathways,
independently from size, shape, and surface charge [35]. )e
mechanism of LSECs internalization of NPs is performed by
clathrin-mediated endocytosis [36]. Sinusoidal endothelial
cells are not only the most permeable endothelial cells of the
body, due to the association of fenestrae and the absence of
typical basement membrane, but also one of the highest
endocytic cells in the human body. )is property combined
with a strong lysosomal activity gives these cells the ability to
remove soluble macromolecules and NPs through pinocytic
receptor-ligand interaction [37]. Some major high affinity
endocytosis receptors are involved, including scavenger re-
ceptors (SR-A, SR-b, and SR-H), mannose receptor, collagen-
alpha receptor, and Fc gamma-receptor [17, 38]. )e SRs,
especially, mediate endocytosis of polyanionic molecules and
also of negatively charged NPs [39, 40].
All these findings highlight that a detailed understanding
of where and how NPs are sequestered and cleared within
the liver is crucial to solve the targeting problem of NPs.
Sinusoidal endothelial cells also differ morphologically;
indeed, periportal cells show fewer and larger fenestrations
in comparison with the same cells in the pericentral region,
impacting the molecules that may access the underlying
hepatocytes [41]. )e zonal heterogeneity affects also NP
distribution at the lobule level; preferential periportal ac-
cumulation was observed for gold NPs coated with PEG and
quantum dots [42].
3. Protein Corona andMacrophage Elimination
When NPs are administered intravenously, they come in
contact with a solution of thousands of proteins (62–84 g/L)
that can be adsorbed on their surface conferring a new
biological identity and influencing their clearance in vivo.
)e adsorption of serum proteins on NPs is termed
“opsonization” and leads to the formation of a dynamic
protein coat known as “protein corona” [43, 44].)e protein
corona is considered to be a continuous flux of desorption/
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Figure 1: Schematic representation of the liver processing causing nanoparticles clearance.
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adsorption processes controlled by the so-called “Vroman
effect”: at any time, an initially attached protein can desorb
from the NP surface and be replaced by a different one with
higher affinity. )is process changes the composition of the
protein corona while the amount of adsorbed proteins re-
mains relatively constant [45–47]. )e generation of the
protein corona is divided into two phases: initially, more
abundant proteins, with low affinity, are rapidly adsorbed on
NPs, and then, they are replaced by less abundant proteins
but with higher affinity, until the corona reaches a stable
composition. )e latter type of proteins binds irreversibly to
the NP surface within seconds or a minute constituting the
“hard corona”; low affinity proteins with fast exchange rates
interact with the hard corona components through protein-
to-protein interactions constituting the “soft corona”
[45, 46, 48].
)e protein corona formation is related to the physi-
cochemical properties (i.e., size, charge, shape, and surface
composition) of NPs and the amount of proteins in the
biological fluid [43, 44] and can be considered unique for
each nanomaterial. )e protein corona contributes to NP
clearance, circulation time, bioavailability, and toxicity,
determining a different interaction with the cells in the body
[43, 44].
)e protein corona plays a fundamental role in the
biodistribution of NPs, and in particular, in the recognition
by the MPS, especially through the adsorption of opsonins
such as immunoglobulin G (IgG), coagulation proteins (i.e.,
fibrinogen), or complement components, which are believed
to promote recognition by specific receptors on macrophage
and phagocytosis [29, 47, 49]. On the contrary, dysopsonins,
such as apolipoprotein J (clusterin) and albumin, were re-
ported to reduce the adsorption of opsonins on the surface of
NPs conferring “stealth properties” [47, 50].
Current research in the field of nanomedicine is focused
on modulating the protein corona formation to minimize
the rapid recognition by MPS and the rapid elimination of
NPs from the body.)e surface of NPs can be modified with
polymers that respond to the four criteria described by
Whitesides and coworkers: hydrophilicity, absence of net
charge and hydrogen bond donors, and presence of hy-
drogen bond acceptors. Among neutral polymers, PEG was
considered the gold standard for protein-resistant surfaces
because it corresponds to all the criteria and prevents ad-
sorption of opsonins on NPs. However, recent studies
demonstrated that the clinical use of such polymer is limited
by its thermal instability, the production of toxic metabolites
after its enzymatic degradation, and the formation of anti-
PEG antibodies after repeated administrations of PEG or
PEG conjugates [42]. In recent years, much attention has
been given to alternatives to PEG, i.e., poloxamer, poly-
vinylpyrrolidone (PVP) and dextran [47]. Other strategies to
prevent MPS engulfment of NPs include (i) the saturation of
receptors expressed on Kupffer cells with nontoxic NPs prior
to administration of a nanotherapeutic [51]; (ii) the specific
transient depletion of macrophages by the injection of
dichloromethylene-bisphosphonate- or clodronate-loaded
liposomes or substances like gadolinium chloride, methyl
palmitate, dextran sulfate, and carrageenan [17, 51]; (iii) bio-
inspired cell-based approaches which consist in using cells,
i.e., red blood cells, platelets, leukocytes, monocytes, and
stem cells as drug delivery systems [52, 53].
4. NP Surface Modification to Improve
Distribution Properties
Polymeric NPs, micelles, nanoemulsions, nanohydrogels,
liposomes, and solid lipid NPs have been developed as
nanodelivery systems mainly for anticancer drugs in HCC
therapy exploiting passive targeting. It is worth noting that
NPs after IV administration accumulate at higher levels in
the liver than in other tissues, if they were not engineered for
other selective targets.
Li et al. [54] described the challenge and the strategies to
overcome the clinical problems of nanosystems for the
treatment of liver diseases, including HCC. A number of
options have been proposed; the most are related to the
modification of NP surface. )is strategy can include either
the coating of the surface or the chemical conjugation with
different molecules or targeting ligands.
Surface modifications can significantly alter the circu-
lation lifetime by changing the surface charge, hydrophobic
capability, targeting capacity, or biocompatibility of NPs
[55].
)e surface charge has a critical impact on the blood
circulation and the biodistribution of nanocarriers, as well as
on their stabilization [56]. Indeed, the surface charge con-
tributes to the electrostatic repulsion between NPs, avoiding
their aggregation, according to DLVO theory. However, the
modulation of the surface charge can be considered an
important balance for the system stabilization and for in vivo
fate of NPs. Different studies investigated the effects of
surface charge of different nanodelivery systems such as
polymeric NPs, micelles on their in vitro cellular uptake by
macrophages, cytotoxic effects, and in vivo biodistribution
in xenograft models [23, 57, 58].
Xiao et al. studied the biodistribution of differently
charged PEG-oligocholic acid-based micelles, showing that
the liver uptake was very high for highly positively or
negatively charged NPs. On the contrary, for micelles with
slightly negative charge, low liver uptake and high tumor
accumulation were observed [57]. Similar insights were
shown in another work that compared the cellular uptake
and biodistribution of negatively charged carboxymethyl
chitosan-grafted NPs and positively charged chitosan hy-
drochloride-grafted NPs. )e results suggested that NPs
with slight negative charge accumulated in the tumor and in
the lesser extent in the liver, while positively charged NPs
showed higher liver and spleen localization [23].
NPs can be modified by coating with ionic or nonionic
polymers. )is approach can limit the interaction with
plasma proteins and phagocytic system, prolonging the
blood residence time.
)e hydrophobicity of NP surface is another key factor
to consider for biodistribution. Indeed, it affects opsoni-
zation, related to capture by the RES and a faster blood
clearance. It was shown that the more hydrophobic the NP
surface is, the higher the absorption of plasma proteins will
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be, after in vivo administration [59]. )e coating with hy-
drophilic polymers/moieties, such as polyethylene glycol
(PEG), polyethylene oxide (PEO), polyvinylpyrrolidone
(PVP), polyacrylic acid, poloxamer, and poloxamine, has
been proven one of the most promising approaches to avoid
opsonization. Hydrophilic polymers on the surface of the
nanocarrier repel other molecules by steric effects [60]. )e
use of PEG moieties on NP surface represents a polymer
shield that can reduce the nonspecific scavenging of
nanotherapeutics by RES. PEG is a neutral and hydrophilic
polymer that can form a hydrophilic flexible barrier layer on
the surface of NPs which produces low opsonization level,
prolonged blood circulation, and the escape from the
phagocytic system. For this behavior, PEG-coated nano-
carriers are called stealth NPs [61]. A large number of studies
highlight that the capability of PEGylation to mask the
nanocarrier surface hydrophobicity/charge is largely affected
on its properties, such as its length, density, and confor-
mation [62]. Interestingly, PEG-modified PLGA NPs
showed a five-fold increase in cell uptake than the un-
modified NPs.
Gao and coworkers developed protamine surface-
modified PLGA-b-PEG-b-PLGA NPs for the delivery of
paclitaxel to the liver. )ese NPs were easily internalized by
HCC cell line HepG2.)e high cellular uptake was shown to
be related to protamine modification. More recently, an-
other paclitaxel-loaded PLGA NPs for the treatment of liver
cancer were designed by Mandal et al.; prolonged half-life
and higher plasma and liver drug concentrations were ob-
served compared to the free drug in rats [63].
)e modification of NPs with hydrophilic polysaccha-
rides is an alternative to PEGylation to modify pharmaco-
kinetic parameters of NPs [64]. Iron-oxide magnetic NPs
were coated with carboxymethyl dextran or dextran, and the
NP biodistribution was studied in mouse models. )e
coating layer minimized the interactions between the iron
core and plasma proteins and enhanced the circulation time.
Iron deposition from NPs possessing a negative surface
potential was observed to have higher accumulation in the
liver and spleen [65].
Chitosan and its derivatives have been exploited as the
hydrophilic coating material for different nanoparticulated
systems. Glycolchitosan-shelled nanobubbles loaded with
doxorubicin showed a strong accumulation at the tumor site
in a xenograft model of anaplastic thyroid cancer [66].
Interestingly, polysaccharide can interact with a particular
receptor of cell membrane. )is phenomenon is exploited
for achieving an active targeting (i.e., hyaluronic acid).
Hyaluronic acid-modified disulfide-crosslinked PLGA-
PEI NPs were developed as a target-specific paclitaxel and
siRNA codelivery system [67]. )ese NPs modified by HA
enhanced tumor targeting efficiency by the CD44 receptor-
mediated uptake of NPs.
Although hydrophilic materials on the surface of NPs
prevent opsonization, hydrophobic characteristics are often
required to increase membrane permeability and cellular
uptake. Amphiphilic copolymers or block copolymers have
shown promising results addressing these issues [60].
5. Targeting Strategies of Drug-Loaded NPs
Nanomedicine offers unique opportunity for an active/
passive targeting to convey drugs to specific target sites
[68, 69]. In the last years, this technology has made re-
markable improvements in NP solubility, stability, bio-
compatibility, and release profile of the drugs [70, 71].
)e passive-targeting approach depends on the drug-
loaded NPs physiochemical properties, administration route
and, most importantly, on the EPR effect of the tumor
vasculature [72]. Specifically, NPs can be accumulated at the
tumor site due to the leaky architecture between endothelial
cells and the poor lymphatic drainage. NPs can concentrate
in the tumor microenvironment for a long time due to the
insufficient venous and lymphatic clearance [73]. Several
studies reported that different compositions of NPs, ranging
from 10 nm to 200 nm, penetrated the leaky vessel walls
around the tumor also due to an EPR effect [74–77]. Fur-
thermore, significant antitumor activities, like tumor re-
gression and long-term survival, were observed when
therapeutic NPs were used. Kim et al. showed that the
prolonged blood circulation of the chitosan-based NPs in-
duced higher EPR efficiency of the NPs [78]. Yhee described
that particle size, particle shape, and surface charge of NPs
also affected their blood circulation time and EPR effect [79].
Although passive targeting is currently the most in-
vestigated mechanism requested in cancer nanomedicine,
including HCC treatment, the rapid clearance rate of
nanostructures restricts their use [80–87].
)erefore, to increase the accumulation of NPs at the
tumor site, the active targeting approach is extensively being
explored. In particular, this approach takes advantage of the
use of a ligand which binds preferentially to tumor cells, thus
increasing the accumulation rate of drug-loaded NPs in the
tumor region [88, 89]. In vitro models showed that the
accumulation rate of targeting tumor NPs was higher than
controls [26].
In the context of HCC, specific markers are being ex-
plored for site-specific delivery of anticancer drugs. )e
asialoglycoprotein receptor (ASGPR) is expressed in well-
differentiated forms of HCC cells. )e expression of this
receptor occurs in early and advanced HCC patients, and it
is one of the most studied targets to selectively deliver
anticancer drugs to HCC [27, 82]. )is receptor has binding
affinity to a long range of molecules containing galactose and
N-acetyl-galactosamine residues such as lactose, galactoside,
galactosamine, and lactobionic acid, and asialofetuin, which
could be conjugated to the surface of NPs for active targeting
[27]. Several studies reported an improved cytotoxic effect in
HCC cells [72, 90].
Glycyrrhizin/glycyrrhetinic acid receptor is also employed
in HCC drug targeting. Glycyrrhetinic acid, a pentacyclic
triterpenoid, is abundantly expressed on the cellular mem-
brane of HCC cells. Several kinds of glycyrrhetinic acid re-
ceptor-targeted polymers were used to deliver doxorubicin, 5-
fluorouracil, and paclitaxel in polymeric NPs to HCC cells
[91–95]. A high accumulation in HCC cells associated with
tumor growth inhibition was observed [72, 96].
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Transferrin receptor (TfR) is overexpressed in many
malignant cells, including HCC, and has become a prom-
ising target for potential treatment [97]. TfR-modified NPs
loaded with doxorubicin and cisplatin showed a higher
cytotoxicity when targeting human HepG2 cells than
nontargeting NPs [98, 99].
Folate receptors (FR) are glycosylphosphatidylinositol
(GPI) membrane-anchored glycoproteins overexpressed in
HCC compared to the normal liver. )e natural ligand for
this receptor is the folic acid, and its use is being explored for
NP drug delivery in these cancer cells [90, 100].
Glypican-3 (GPC3), another GPI-anchored protein, is
highly expressed in most liver cancers, but absent or
expressed at very low levels in normal adult tissues
[101–103]. )e conjugation of an anti-GPC3 antibody to
NPs was explored as a drug delivery system. In vitro and in
vivo experiments showed that the use of anti-GPC3 poly-
meric NPs loaded with sorafenib inhibited HepG2 cell
proliferation. )erefore, this drug delivery system could be a
potential tool for the targeted treatment of liver cancer [104].
CD44 is a cell adhesion glycoprotein expressed on cel-
lular surface and involved in immune recognition, cell-
matrix interactions, and cell migration. Patients with HCC
overexpress CD44, and this expression is associated with
tumor growth, metastasis, and poor prognosis [105]. CD44-
targeted liposomes were explored as a potential system for
drug delivery targeting in HCC [106]. In vitro data reported
that anti-CD44 antibody-mediated liposomal NPs loaded
with doxorubicin efficiently targeted the HCC cells com-
pared to normal liver cells and significantly reduced tumor
growth [82, 107].
5.1. Agents for Active Targeting. One of the breakthroughs in
modern medicine involves the use of highly specific mol-
ecules for antigens expressed or overexpressed on particular
cell types or for the recognition of a particular pathological
tissue in order to increase therapeutic efficacy with lower
dosages. )e ultimate goal of this rationale is to reduce the
toxicity caused by off-target effects. Surely, the revolutionary
discovery made by Ko¨hler and Milstein [108] for the pro-
duction of antibodies has paved the way to the so-called
targeted therapy. Nowadays, there are many successful drugs
based on this technology that has allowed the targeting of
specific receptors, or “signature” molecules of particular
tissues. However, in addition to antibodies, other targeting
systems have been developed. Among these molecules, there
are a large group of antibody fragments, small peptides,
nucleic acids such as aptamers, vitamins, and carbohydrates
[109]. )is approach potentially increases therapeutic effi-
cacy, avoiding off-target side effects. Moreover, a reduction
in costs of disease management is expected because the doses
required to achieve the same efficacy compared to untar-
geted drugs might be lower [110].
5.1.1. Recombinant Antibodies and ,eir Fragments.
From the phylogenetical point of view, the antibodies are
proteins found in many different jawed vertebrates such as
fish, camels, rodents, and humans [111]. )e antibodies are
heterodimeric proteins composed of two structural elements
defined as Heavy (H) and Light (L) chains because of their
aminoacidic composition and molecular weight. )e heavy
chain is made of 440aa with a molecular weight of 50 kDa,
whereas the light counterpart consists of 220aa with a
molecular weight of 25 kDa [112]. Each chain can be divided
into two basic building blocks: the variable (V) domain
(NH2-terminal), able to interact with the antigen, and the
constant (C) domain (COOH-terminal), responsible for the
effector functions such as macrophages binding or com-
plement system activation. )e heavy chain differs from the
light chain for the number and composition of these
functional domains: the light chain contains one constant
domain (CL), whereas the heavy chain could be composed
by either three or four constant domains (CH). A spacer
hinge region is located between CH1 and CH2 and confers
particular flexibility to the final structure [113]. Depending
on the constant composition, the human heavy chains could
be classified into 5 isotypes: IgM, IgG, IgA, IgD, and IgE.)e
classes IgM and IgE have four CHs in contrast with the
others, which have only three constant domains and the
hinge region. In the variable domain, three hypervariable
loops are responsible for the antigen identification, called
complementarity determining region (CDR) [114].
Antibody functional domains can be identified by en-
zymatic digestion: two identical Fab, “fragment antigen-
binding,” which consist of the whole L-chain linked with the
VH and the CH1 portion of the heavy chain can be produced
using papain. Instead, the immunoglobulin can be cleaved
by pepsin producing F(ab′)2 fragment and a Fc fragment.
)e Fab can be separated into a variable fragment (Fv), made
of VH and VL and responsible for the antigen binding.
Taking advantage of these functional domains, different
targeting molecules have been designed and produced by
recombinant technology. Improvement of the molecular
biology technique allows researchers to reduce the murine
component of monoclonal antibodies in favor of the human
component, generating different kinds of antibodies such as
chimeric, humanized, or fully human. )e most successful
engineered antibodies used are the scFv (single-chain
fragment variable) or Fab. However, in order to improve
their monovalent binding, diabodies have been produced;
they consist of two scFvs fused together through a linker.
Some issues are associated with their small molecular size:
fast clearance and poor stability. In order to solve these
problems, two different engineered antibodies have been
designed: the scFv-Fc, made of the scFv fused to the CH3-
CH2 portion, and the so-called “minibody,” made of the
scFv fused to the only CH3.)ese formats showed improved
pharmacokinetics, with a prolonged circulation time, in-
creased tissue penetration, and enhanced epitope selectivity
[115].)en, the scFv-Fc has been implemented with homing
peptides fused at the end of the CH3, giving this molecule a
double binding capacity. It is the case of an anti-C5 fused to a
synovial tissue homing peptide, capable to block the C5 of
the complement system specifically into the inflamed sy-
novial tissue [116, 117]. Using the same strategy, the same
scFv-Fc has been fused to the RGD peptide in order to
specifically block the complement system onto the
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endothelium of inflamed kidneys [118]. Following the ra-
tionale to produce an antibody with a double specificity,
bispecific antibodies have been generated. )ese kinds of
antibodies are made of two different monomers, which, due
to a knob into hole mechanism, are able to self-assemble in a
scFv-Fc antibody [119]. According to this strategy, a bis-
pecific antibody can be generated, one arm of the molecule
with an antigen tissue specificity and the other one able to
block an inflammatory cytokine [3] or a protein of the
complement system [120].
5.1.2. scFv to Target Cancer. Several scFvs have been
identified and tested in preclinical studies to target and treat
many different pathologies encompassing autoimmune
[121], neurological [122], and oncological diseases [123]. A
number of studies have been carried out to isolate scFvs
capable of specifically targeting signature proteins of a
particular cancer cell, mainly exploiting the phage display
technology [124]. Many scFvs have been generated against
known proteins overexpressed by a number of different
kinds of cancer cells, such as HER [125] and EpCAM [126],
or against target proteins that are essential for cancer growth
and spreading, such as VEGF [127] (involved in neo-an-
giogenesis). Recently, a novel scFv able to bind CD24, a
target overexpressed by hepatocellular carcinoma (HCC),
has been developed, showing a higher accumulation in the
hepatocellular carcinoma xenograft mouse model and
proving its potential as a therapeutic and diagnostic agent
[128]. Another promising target expressed by malignant
hepatocytes called Glypican-3 (GPC3) has already been
exploited to isolate different scFvs with future potential
applications [129, 130].
5.1.3. Peptides as Targeting Agents. Although antibodies are
used as targeting agents able to delivery nanocarriers in a
specific tissue, recently peptides have been used with great
success. Due to their small size, high stability, low immu-
nogenicity, and easy production, peptides have huge po-
tential as targeting agents [110, 131]. Peptides containing the
aminoacidic sequence Arg-Gly-Asp (RGD) are able to bind
integrins αvβ3, which are expressed on endothelial cells of the
inflamed tissue and tumors. Indeed, in a mice model of a
syngeneic transplantable liver tumor, a retarded tumor
growth and a prolonged survival time of mice treated with
paclitaxel- (PTX-) loaded RGD-NPs have been demon-
strated when compared to nontargeted NPs [132]. In the
same way, it has been proved that RGD-MTX-PLGA-Au
NPs injected into a model of collagen-induced arthritis had a
superior therapeutic efficacy, compared with untargeted
NPs, with a much smaller dosage of MTX in the NPs [133].
More recently, Gao et al. tested RGD-coated nanodots as the
theranostic agent for HCC, both in vitro and in vivo [134].
Another well-known peptide used to target endothelial cells
of cancer blood vessels is the Asn-Gly-Arg (NGR). It binds
the CD13 expressed on tumor endothelial cells and in a
clinical trial, the NGR, conjugated with the human tumor
necrosis factor (NGR-hTNF), showed no toxic effects and a
progression-free survival (PFS) rate of 2.3months compared
with the control group [135]. Other peptides have been
isolated to target chronic inflammatory diseases like rheu-
matoid arthritis. Indeed, Lee et al. have isolated a peptide
with specificity for the human arthritic synovium, in par-
ticular, for the inflamed microvasculature, by injecting a
phage display library in the human synovium-SCID mouse
transplantation model [136, 137]. )is peptide allows a
selective delivery of polymeric NPs in synovial tissue and an
effective therapeutic control of the inflammatory process
[138].
Figure 2 summarizes the structure of a full immuno-
globulin with the VL, VH, CL, and CH. )en, fragments
such as F(ab)2 and Fab’ and other formats like scFv and scFv-
Fc are reported. Finally, there are represented by small
targeting molecules such as peptides and aptamers (figures
adapted from Reference [109]).
6. Clinical Trials Investigating the Use of NP-
Based Therapy for HCC Treatment
To date, there are several available therapies in clinical use
(like resection or radio frequency ablation (RFA), trans-
arterial chemoembolization (TACE) or radioembolization,
and chemotherapy) [139]. However, it still remains a
treatment challenge to overcome the actual poor survival
rate, in particular, regarding the advanced-staged hepato-
cellular carcinoma (HCC) patients (<5%) [140].
Many NP formulations of anticancer drugs are approved
for human use and are already available in the market
[141–143]. In the HCC field, there is only one nanodrug
clinically approved in Europe and Asia, the doxorubicin-
eluting beads trans-arterial chemoembolization (TACE).
Compared to the conventional TACE, this technology exerts
both the therapeutic components of TACE, that is, the drug-
carrier function and embolization, thus minimizing the risk
of systemic drug [144]. )e beads are composed of a hy-
drophilic, ionic polymer that can bind and load the drug (i.e.,
doxorubicin) positively charged. After its administration in
liver tumor by intra-arterial injection, these microspheres
begin to slowly release the doxorubicin in a controlled
manner [145–147]. However, despite promising results of
doxorubicin DEB-TACE, novel nanotechnologies are cur-
rently being investigated in clinical trials (Table 1).
Currently, there are 3 clinical trials for HCC treatment in
phase III involving nanostructures, whose endpoint is to
investigate the antitumoral efficacy.
)e OPTIMA clinical trial (NCT02112656) aimed to
determine the )ermodox technology efficacy in the treat-
ment of non-resettable HCC. )is novel nanomedicine
composition is based on liposomes which encapsulate
doxorubicin. When heated by the application of RFA (to
39–42°C), the heat-sensitive liposomes change their struc-
ture creating openings that release doxorubicin directly into
and around the targeted tumor (https://clinicaltrials.gov/ct2/
show/study/NCT02112656?term�OPTIMA+celsion&rank�1)
[80, 148]. )is study is still ongoing (http://investor.celsion.
com/news-releases/news-release-details/celsion-announces-
enrollment-completion-pivotal-phase-iii-optima).
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)e ADI-PEG 20 clinical trial (NCT01287585) is based
on the use of an arginine deiminase (ADI) enzyme conju-
gated with polyethylene glycol (PEG) to treat patients with
advanced HCC who failed prior systemic therapy [81]. )e
role of this enzyme is to deplete the circulating arginine
necessary for the HCC cell proliferation. )e study reported
that the administration of ADI PEG 20 was safe, well tol-
erated by patients but did not significantly improve overall
survival (https://clinicaltrials.gov/ct2/show/NCT01287585?
term�NCT01287585&rank�1) [82]. However, a trend of
improved survival was observed in the subgroup of patients
with low levels of circulating arginine (<10 µM). )erefore,
new studies will focus on the potential effect of this aspect
[149].
)e Livatag study (NCT01655693) investigated whether
Doxorubicin Transdrug (DT) is effective in the treat-
ment of patients affected by advanced HCC after failure
or intolerance to Sorafenib treatment. DT is a NP formu-
lation of doxorubicin obtained with water insoluble pol-
y(iso-hexyl-cyanoacrylate) polymer. )is formulation
easily delivers the drug into the tumor cell increasing the
drug payload in the DNA target, thereby bypassing
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Figure 2: Schematic representation of potential agent for active targeting of nanostructures.
Table 1: )e reported clinical trials investigating the use of nanostructures whose endpoint is the treatment of hepatocellular carcinoma.
Clinical trial name Phase NP type NP target Trial number
OPTIMA III Heat-sensitive liposome, doxorubicin loaded Non-active targeting NCT02112656
ADI-PEG 20 III Polyethylene glycol (PEG) conjugated with argininedeaminase (ADI) enzyme Depletion of arginine NCT01287585
Livatag study III Formulation of doxorubicin with water insolublepoly(iso-hexyl-cyanoacrylate) polymer Non active targeting NCT01655693
TKM-080301 study I/II Short-interference RNA (siRNA) within a lipidparticle
Downregulation of polo-like
kinase 1 (PLK-1) protein NCT02191878
NBTXR3 study II/III
Hafnium oxide NPs developed to increase the
tumor-localized high energy deposit once activated
by ionizing radiation such as stereotactic body
radiotherapy (SBRT) and thus increasing
tumor cell death compared to the same dose
of radiation
Non-active targeting
NCT02379845;
NCT01946867;
NCT02901483.
DCR-MYC study I Double-stranded RNA in a stable lipid particlesuspension
Downregulation of oncogene
c-myc NCT02314052
MRX34 study I Double stranded RNA which mimics microRNA-34a(miR-34a) within liposomal NPs
Downregulation of miR-34a
targets NCT01829971
MTL-CEBPA study I Short activating RNAs (saRNA) withinliposomal NPs
Downregulation of CCAAT
enhancer binding protein
alpha (CEBPA) gene
NCT02716012
NCT, number of clinical trials.
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the mechanisms of multidrug resistance devel-
oped by tumor cells (https://clinicaltrials.gov/ct2/show/
NCT01655693?term�NCT01655693&rank�1; https://www.
onxeo.com/onxeo-announces-top-line-results-relive-phase-
iii-study-livatag-advanced-hepatocellular-carcinoma/) [82].
)e current phase I/II clinical trials for HCC treatment
involving nanostructures, whose final endpoint was the
evaluation of the nanodrug toxicity and safety, are listed as
follows.
)e TKM-080301 study (Arbutus Biopharma,
NCT02191878) is based on the use of TKM-080301 that is
composed of a short-interference RNA (siRNA) within a
lipid particle, capable to be accumulated within tumors,
taking advantage of the “enhanced permeation and retention
(EPR)” effect [83, 150]. )e siRNA target is the polo-like
kinase 1 (PLK-1) protein which is overexpressed in HCC
cells (up to 12-fold higher compared to controls) and
promotes cell proliferation. In vitro data showed that in-
hibition of PLK1 activity in proliferating cancer cells rapidly
induces mitotic arrest and apoptosis [151] and increases the
sensitivity of cancer cells to the cytotoxic effects of che-
motherapy [84].
)e lipid components of TKM-080301 also protect the
siRNA from degradation by plasma and tissue nucleases,
prevent rapid clearance of the siRNA, and enable effective
intracellular uptake of the PLK1-targeting siRNA into
cancer cells [152]. )e study was declared to be concluded in
February 2019, and preliminary data results showed that this
treatment was safe and well tolerated. )e next endpoint of
the study is to evaluate the antitumor activity of TKM-
08030120.
A second study is the NBTXR3 study (Crystalline NPs
and Stereotactic Body Radiation)erapy in the Treatment of
Liver Cancers, NCT02721056). )is study aimed to evaluate
the safety and tolerability of NBTXR3, NPs administered by
intralesional (IL) or intra-arterial (IA) injection and acti-
vated by Stereotactic Body Radiation )erapy, in the
treatment of HCC. NBXTR3 is constituted by hafnium oxide
NPs developed to increase the tumor-localized high energy
deposit once activated by ionizing radiations such as ste-
reotactic body radiotherapy (SBRT) and thus increasing
tumor cell death compared to the same dose of radiation.
From preliminary data, NBTXR3 showed no toxicity and
was well tolerated. Evaluated in other tumors, NBTXR3 was
successful in a phase II/III trial in soft tissue sarcoma
(NCT02379845) and is currently being evaluated in head
and neck (NCT01946867; NCT02901483), prostate
(NCT02805894) and rectum cancers (https://clinicaltrials.
gov/ct2/show/NCT02721056?term�NCT02721056&rank)
(http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.
15_suppl.e16194) [153].
)e DCR-MYC study (NCT02314052, Dose Escalation
Study of DCR-MYC in patients with Hepatocellular Car-
cinoma) was designed for solid tumors including HCC.)is
nanodrug is a synthetic double-stranded RNA in a stable
lipid particle suspension that targets the oncogene c-myc.
)e oncogene c-myc is abnormally expressed in tumors and
implicated in promoting cancers [85, 142]. DCR-MYC is a
Dicer substrate small interfering RNA (DsiRNA), a double-
stranded synthetic RNA within a stable lipid particle, which
specifically targets the oncogene c-myc (https://clinicaltrials.
gov/ct2/show/results/NCT02314052?view�results).
MRX34 (mirna )erapeutics, PhI, NCT01829971) is a
synthetic double-stranded RNA which mimics microRNA-
34a (miR-34a), a miRNA that downregulates the expression
of >30 oncogenes across multiple oncogenic pathways, but it
is lost or underexpressed in many malignancies. Contra-
dictory information was reported on a number of occasions,
especially with the use of a miRNA-34a inhibitor for HCC,
making it difficult to evaluate a clear clinical benefit of this
potential therapy [86].
)e MTL-CEBPA study in patients with advanced liver
cancer (NCT02716012) evaluated the safety and tolerabil-
ity of a “short” activating RNA (saRNA) in HCC patients
[87]. MTL-CEBPA comprises a double-stranded RNA
inside liposomal NPs which specifically target the CEBPA
gene. Downregulation of the CEBPA gene showed to
inhibit the HCC tumor growth in preclinical models [154].
MTL-CEBPA is the first saRNA and the first drug targeting
C/EBP-α to enter clinical trials. To date, the study is still
ongoing (https://clinicaltrials.gov/ct2/show/NCT02716012?
term�NCT02716012&rank�1; http://ascopubs.org/doi/10.
1200/JCO.2017.35.15_suppl.TPS2612).
7. Conclusions
)e development of nanostructures for therapeutic purpose
is rapidly growing, following the results obtained in vivo in
animal models and in the clinical trials. Information col-
lected up to now confirmed the safety of this therapeutic
approach. Unfortunately, the potential therapeutic efficacy is
not completely exploited, yet. )is is mainly due to the fast
clearance of the nanostructures in the body and liver was
immediately shown as the organ deputized to a fast
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Figure 3: Schematic representation of the factor influencing se-
lective delivery of nanoparticles developed for HCC treatment.
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elimination. Physicochemical modification of NP surface, as
well as changes in their shape, provide the possibility to
increase the half-life of the nanostructures and enhance their
possibility to take advantage of the EPR effect in cancer or
inflammatory microenvironment.
)e application of nanomedicine in liver diseases, and in
particular in HCC, represents the most evident example of
the limits in the application of these therapeutic approaches.
)e leaky vessels of the liver have similar characteristics of
the leaky vessels in cancer; the presence of macrophages,
endothelial cells and hepatocytes tends to phagocytes
nanostructures; the interaction of the particles with plasma
proteins enhance their fast elimination. )e result is a very
low accumulation of the nanosystems in the pathological
part of the liver. In the on-going clinical trials, the treatments
of HCC using NPs for the delivery of different drugs
demonstrated their safety but exploit only EPR effect in
contrast with the elimination effect caused by the healthy
structures of the liver.
A possible turning point could be the use of targeting
agents covalently bind of particle surface; this approach
demonstrated a superior therapeutic effect in different an-
imal models. Its application depends from the individuation
of specific tumor-associated antigens and from the devel-
opment of molecules avidly able to bind them. Recent
studies have individuated several molecules that can rep-
resent possible targets for the selective delivery of targeted
NPs. )is probably represents the next step in the nano-
medicine for the treatment of HCC, as summarized in
Figure 3.
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